TP53 and neoplasm: APG-115 inhibits the interaction between MDM2 and p53, which promotes the activation of p53 in tumor microenvironment immune cells, resulting in increased infiltration of CD8+ T cells and M1 macrophages while reduced infiltration of M2 macrophages, enhancing the anti-PD-1 antibody anti-tumor immune efficacy.148